ZNTL
Zentalis Pharmaceuticals, Inc.
$3.75
+6.53%
$266.9M
No data for this timeframe.
Vol
Market Cap$266.9M
Cap SizeMicro Cap
Analyst ConsensusBuy (60%)
Inst. Holders45 funds
Inst. Value$44.5M
Inst. Activity4 buys / 7 sells
Insider Activity0B / 9S
Insider Net $-$134.7K
SEC Reports7
Press Releases4
Recent Activity
Jun 11, 2026
SEC
Institutional cluster for ZNTL in Q3 2024 reveals a mixed picture: D.E. Shaw doubled its position to $4.2M and Balyasny
INST-CLUSTER — Impact 4/10
Jun 3, 2026
short_volume
Short Volume: ZNTL — 71.4% short (0.4M / 0.5M)
Short: 381,699 | Exempt: 1,156 | TRF Vol: 534,478 | Short Ratio: 71.4% | Off-exchange volume (dark p
Jun 1, 2026
Press
Zentalis granted 191,000 non-qualified stock options to two newly hired employees as an inducement for employment, with
Impact 2/10
May 26, 2026
Insider
Campbell Shannon was granted 114,200 shares
Director
May 21, 2026
SEC
Zentalis announced positive Phase 1b data for azenosertib plus paclitaxel in platinum-resistant ovarian cancer, with 39%
PRESS-RELEASE — Impact 6/10
May 21, 2026
SEC
Zentalis Pharmaceuticals announced Phase 1b MUIR trial data for azenosertib plus paclitaxel in platinum-resistant ovaria
8-K — Impact 6/10
Feb 10, 2026
Insider
Vultaggio Vincent sold 6,894 shares
PAO and PFO @ $2.42 ($16.7K)
Feb 9, 2026
Insider
EASTLAND JULIA MARIE sold 889 shares
CEO & President @ $2.39 ($2.1K)
Price Targets
$6.50
+73.3% upside
Strong Buy
Current $3.75
Low $4.00
Median $5.50
High $10.00
8 analysts
$4.00
$10.00
Analyst Ratings
4Strong Buy
5Buy
6Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Apr 10, 2026 | Guggenheim | MAINTAIN | Buy → Buy |
| Mar 27, 2026 | Guggenheim | REITERATE | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.46 | $-0.59 — $-0.30 | -25% YoY | 7 |
| Next Q | $-0.49 | $-0.64 — $-0.31 | -32% YoY | 7 |
| Current FY | $-1.74 | $-2.19 — $-1.33 | 3% YoY | 5 |
| Next FY | $-1.56 | $-2.32 — $-0.87 | 10% YoY | 7 |
Latest Reports
MIXED
INST-CLUSTER
4/10
Institutional cluster for ZNTL in Q3 2024 reveals a mixed picture: D.E. Shaw doubled its position to $4.2M and Balyasny
Jun 11, 2026
NEUTRAL
Press
2/10
Zentalis granted 191,000 non-qualified stock options to two newly hired employees as an inducement for employment, with
Jun 1, 2026
BULLISH
PRESS-RELEASE
6/10
Zentalis announced positive Phase 1b data for azenosertib plus paclitaxel in platinum-resistant ovarian cancer, with 39%
May 21, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| ROYAL BANK OF CANADA | — | TRIM |
| TWO SIGMA INVESTMENTS, LP | $6.9M | ADD |
| VANGUARD CAPITAL MANAGEMENT LLC | $5.4M | — |
| RENAISSANCE TECHNOLOGIES LLC | $4.5M | TRIM |
| CITADEL ADVISORS LLC | $4.1M | DOUBLED |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 26, 2026 | Campbell Shannon | A | $0.00 |
| Feb 10, 2026 | Vultaggio Vincent | SELL | $16.7K |
| Feb 9, 2026 | EASTLAND JULIA | SELL | $2.1K |
| Feb 9, 2026 | Vultaggio Vincent | SELL | $8.1K |
| Feb 9, 2026 | Bruns Ingmar | SELL | $801.62 |
45 institutional holders with $44.5M total value (19,069,977 shares) as of 2026-Q1. Top holders: ROYAL, TWO, VANGUARD. Net selling activity: 7 institutions trimmed/exited vs 4 added.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | ROYAL BANK OF CANADA | 98 | $0.00 | 0.0% | TRIM -61.3% |
| 2 | TWO SIGMA INVESTMENTS, LP | 2,956,526 | $6.9M | 15.5% | ADD +99.0% |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 2,310,707 | $5.4M | 12.1% | — |
| 4 | RENAISSANCE TECHNOLOGIES LLC | 1,938,145 | $4.5M | 10.2% | TRIM -32.8% |
| 5 | CITADEL ADVISORS LLC | 1,732,083 | $4.1M | 9.1% | DOUBLED +349.3% |
| 6 | D. E. Shaw & Co., Inc. | 1,484,098 | $3.5M | 7.8% | — |
| 7 | BlackRock, Inc. | 1,269,837 | $3.0M | 6.7% | TRIM -28.3% |
| 8 | BANK OF AMERICA CORP /DE/ | 1,132,294 | $2.6M | 6.0% | DOUBLED +117.1% |
| 9 | Connor, Clark & Lunn Investment Management Ltd. | 792,001 | $1.9M | 4.2% | DOUBLED +106.7% |
| 10 | BARCLAYS PLC | 591,217 | $1.4M | 3.1% | DOUBLED +16146900.0% |
| 11 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 571,257 | $1.3M | 3.0% | — |
| 12 | GOLDMAN SACHS GROUP INC | 462,678 | $1.1M | 2.4% | — |
| 13 | MARSHALL WACE, LLP | 392,643 | $918.8K | 2.1% | ADD +58.5% |
| 14 | VANGUARD PORTFOLIO MANAGEMENT LLC | 360,600 | $843.8K | 1.9% | — |
| 15 | MORGAN STANLEY | 350,207 | $819.5K | 1.8% | TRIM -56.4% |
| 16 | VANGUARD FIDUCIARY TRUST CO | 304,471 | $712.5K | 1.6% | — |
| 17 | FMR LLC | 283,917 | $664.4K | 1.5% | — |
| 18 | DIMENSIONAL FUND ADVISORS LP | 272,034 | $634.3K | 1.4% | DOUBLED +182.6% |
| 19 | Woodline Partners LP | 266,032 | $622.5K | 1.4% | TRIM -49.9% |
| 20 | STATE STREET CORP | 249,690 | $584.3K | 1.3% | NEAR_EXIT -79.4% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 2,883,745 | 1,938,145 | -32.8% | $4.5M | 2026-Q1 |
| MARSHALL WACE, LLP | ADD | 247,788 | 392,643 | +58.5% | $918.8K | 2026-Q1 |
| MORGAN STANLEY | TRIM | 803,654 | 350,207 | -56.4% | $819.5K | 2026-Q1 |
| DIMENSIONAL FUND ADVISORS LP | DOUBLED | 96,263 | 272,034 | +182.6% | $634.3K | 2026-Q1 |
| Woodline Partners LP | TRIM | 530,582 | 266,032 | -49.9% | $622.5K | 2026-Q1 |
| PANAGORA ASSET MANAGEMENT INC | ADD | 86,640 | 139,690 | +61.2% | $326.9K | 2026-Q1 |
| Invesco Ltd. | TRIM | 188,582 | 125,767 | -33.3% | $294.3K | 2026-Q1 |
| WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | TRIM | 130,407 | 78,740 | -39.6% | $207.1K | 2026-Q1 |
| FEDERATED HERMES, INC. | ADD | 34,574 | 65,520 | +89.5% | $153.3K | 2026-Q1 |
| Universal- Beteiligungs- und Servicegesellschaft mbH | TRIM | 51,061 | 22,447 | -56.0% | $52.5K | 2026-Q1 |
| CWM, LLC | TRIM | 8,564 | 5,377 | -37.2% | $12.6K | 2026-Q1 |
| MORGAN STANLEY | TRIM | 1,407,829 | 803,654 | -42.9% | $1.1M | 2025-Q4 |
| Connor, Clark & Lunn Investment Management Ltd. | DOUBLED | 380,822 | 787,055 | +106.7% | $1.1M | 2025-Q4 |
| DIMENSIONAL FUND ADVISORS LP | TRIM | 185,032 | 96,263 | -48.0% | $129.9K | 2025-Q4 |
| CWM, LLC | TRIM | 13,118 | 8,564 | -34.7% | $12.00 | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 1,529,553 | 2,325,355 | +52.0% | $3.5M | 2025-Q3 |
| CITADEL ADVISORS LLC | DOUBLED | 462,340 | 2,077,290 | +349.3% | $3.1M | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 713,315 | 1,548,781 | +117.1% | $2.3M | 2025-Q3 |
| MORGAN STANLEY | ADD | 1,097,651 | 1,407,829 | +28.3% | $2.1M | 2025-Q3 |
| BlackRock, Inc. | TRIM | 1,741,747 | 1,249,504 | -28.3% | $1.9M | 2025-Q3 |
| UBS Group AG | DOUBLED | 129,468 | 532,678 | +311.4% | $804.3K | 2025-Q3 |
| DIMENSIONAL FUND ADVISORS LP | TRIM | 335,966 | 185,032 | -44.9% | $279.4K | 2025-Q3 |
| BARCLAYS PLC | DOUBLED | 1 | 161,470 | +16146900.0% | $243.8K | 2025-Q3 |
| AMERIPRISE FINANCIAL INC | TRIM | 91,195 | 52,572 | -42.4% | $79.4K | 2025-Q3 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEAR_EXIT | 299,097 | 41,981 | -86.0% | $63.4K | 2025-Q3 |
4 unique insiders with 10 transactions. Net insider value: -$134.7K ($0.00 bought, $134.7K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 26, 2026 | Campbell Shannon | Director | AWARD | 114,200 | — | — |
| Feb 10, 2026 | Vultaggio Vincent | PAO and PFO | SELL | 6,894 | $2.42 | $16.7K |
| Feb 9, 2026 | EASTLAND JULIA MARIE | CEO & President | SELL | 889 | $2.39 | $2.1K |
| Feb 9, 2026 | Vultaggio Vincent | PAO and PFO | SELL | 3,379 | $2.39 | $8.1K |
| Feb 9, 2026 | Bruns Ingmar | Chief Medical Officer | SELL | 335 | $2.39 | $801.62 |
| Feb 6, 2026 | EASTLAND JULIA MARIE | CEO & President | SELL | 7,866 | $2.43 | $19.1K |
| Feb 6, 2026 | Vultaggio Vincent | PAO and PFO | SELL | 29,951 | $2.43 | $72.8K |
| Feb 6, 2026 | Bruns Ingmar | Chief Medical Officer | SELL | 2,962 | $2.43 | $7.2K |
| Feb 3, 2026 | Vultaggio Vincent | PAO and PFO | SELL | 556 | $2.52 | $1.4K |
| Feb 2, 2026 | Vultaggio Vincent | PAO and PFO | SELL | 2,540 | $2.55 | $6.5K |
7 SEC filing reports analyzed. Sentiment: 6 bullish, 0 bearish, 1 mixed, 0 neutral. Avg impact: 6.3/10.
MIXED
INST-CLUSTER
4/10
Institutional cluster for ZNTL in Q3 2024 reveals a mixed picture: D.E. Shaw doubled its position to
Jun 11, 2026
BULLISH
PRESS-RELEASE
6/10
Zentalis announced positive Phase 1b data for azenosertib plus paclitaxel in platinum-resistant ovar
May 21, 2026
BULLISH
8-K
6/10
Zentalis Pharmaceuticals announced Phase 1b MUIR trial data for azenosertib plus paclitaxel in plati
May 21, 2026
BULLISH
8-K
7/10
Zentalis reported Q1 2026 results with a net loss of $35.4M ($0.50/share), slightly better than the
May 12, 2026
BULLISH
PRESS-RELEASE
7/10
Zentalis reported Q1 2026 EPS of -$0.50, beating consensus of -$0.52 by 4.5%, with no revenue. The k
May 12, 2026
BULLISH
8-K
7/10
Zentalis Pharmaceuticals presented preclinical data at AACR 2026 showing that its investigational WE
Apr 17, 2026
BULLISH
8-K
7/10
Zentalis Pharmaceuticals announced the selection of 400mg QD 5:2 as the optimal monotherapy dose for
Apr 9, 2026
NEUTRAL
2/10
Zentalis granted 191,000 non-qualified stock options to two newly hired employees as an inducement f
Jun 1, 2026
NEUTRAL
4/10
Zentalis Pharmaceuticals announced that data from Part 1 of its MUIR trial, evaluating azenosertib i
Apr 21, 2026
BULLISH
7/10
Zentalis Pharmaceuticals presented preclinical data at AACR 2026 showing azenosertib, its investigat
Apr 17, 2026
NEUTRAL
5/10
Zentalis Pharmaceuticals reported its 2025 financial results, highlighting a significant reduction i
Mar 26, 2026
Current analyst consensus: Buy (60% buy). Based on 15 analysts: 4 strong buy, 5 buy, 6 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$6.50 mean target
+73.3% upside
Strong Buy (2.11)
$4.00 Low
$10.00 High
| Metric | Value |
|---|---|
| Current Price | $3.75 |
| Target Low | $4.00 |
| Target Mean | $6.50 |
| Target Median | $5.50 |
| Target High | $10.00 |
| # Analysts | 8 |
| Recommendation | Strong Buy (2.11) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.46 | $-0.59 | $-0.30 | -24.7% | +0.0% | — | $0.0B | 0.0% | 7 |
| Next Q 2026-09-30 |
$-0.49 | $-0.64 | $-0.31 | -31.7% | +0.0% | — | $0.0B | 0.0% | 7 |
| Current FY 2026-12-31 |
$-1.74 | $-2.19 | $-1.33 | 3.5% | +0.0% | 0↑ 1↓ | $0.0B | 0.0% | 5 |
| Next FY 2027-12-31 |
$-1.56 | $-2.32 | $-0.87 | 10.4% | +0.0% | 1↑ 3↓ | $0.0B | 0.0% | 7 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.461 | |
| 7d ago | $-0.461 | |
| 30d ago | $-0.461 | |
| 60d ago | $-0.543 | +0.082 |
| 90d ago | $-0.528 | +0.067 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Apr 10, 2026 | Guggenheim | MAINTAIN | Buy | Buy |
| Mar 27, 2026 | Guggenheim | REITERATE | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 4 | 5 | 6 | 0 | 0 | 60% | |
| May 1, 2026 | 4 | 5 | 6 | 0 | 0 | 60% | |
| Apr 1, 2026 | 4 | 5 | 6 | 0 | 0 | 60% | |
| Mar 1, 2026 | 4 | 5 | 6 | 0 | 0 | 60% | |
| Feb 1, 2026 | 4 | 5 | 6 | 0 | 0 | 60% | |
| Jan 1, 2026 | 4 | 5 | 6 | 0 | 0 | 60% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 3, 2026
short_volume
Short Volume: ZNTL — 71.4% short (0.4M / 0.5M)
Short: 381,699 | Exempt: 1,156 | TRF Vol: 534,478 | Short Ratio: 71.4% | Off-exchange volume (dark pool + OTC)
Jun 2, 2026
short_volume
Short Volume: ZNTL — 64.9% short (0.4M / 0.7M)
Short: 423,953 | Exempt: 300 | TRF Vol: 652,746 | Short Ratio: 64.9% | Off-exchange volume (dark pool + OTC)
Jun 1, 2026
regulatory
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<p align="justify">SAN DIEGO, June 01, 2026 (GLOBE NEWSWIRE) -- Zentalis<sup>®</sup> Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innov
May 21, 2026
earnings
Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026
<p align="justify">SAN DIEGO, May 21, 2026 (GLOBE NEWSWIRE) -- Zentalis<sup>®</sup> Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innova
May 13, 2026
other
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
<p align="justify">SAN DIEGO, May 13, 2026 (GLOBE NEWSWIRE) -- Zentalis<sup>®</sup> Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innova
May 12, 2026
earnings
Zentalis Pharmaceuticals Reports First Quarter 2026 Financial Results and Clinical Progress
<p align="justify">SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- Zentalis<sup>®</sup> Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innova
May 12, 2026
earnings_calendar
ZNTL Q1 2026 Earnings Scheduled — 2026-05-12
May 1, 2026
other
Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
<p>SAN DIEGO, May 01, 2026 (GLOBE NEWSWIRE) -- Zentalis<sup>®</sup> Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing la
Apr 21, 2026
fda
Zentalis Pharmaceuticals Announces Abstract Acceptance at ASCO 2026 Featuring Azenosertib in Combination with Paclitaxel for Platinum-Resistant Ovarian Cancer
Results from Part 1 of the Phase 1b MUIR trial to be presented at annual meeting in June <pre>Results from Part 1 of the Phase 1b MUIR trial to be pre
Apr 17, 2026
fda
Zentalis Pharmaceuticals To Present Azenosertib Preclinical Data in Triple-Negative Breast Cancer and Real-World Analysis of Unmet Need in Cyclin E1-Positive Ovarian Cancer at AACR 2026
<p>SAN DIEGO, April 17, 2026 (GLOBE NEWSWIRE) -- Zentalis<sup>®</sup> Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing
Apr 1, 2026
other
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<p align="justify">SAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE) -- Zentalis<sup>®</sup> Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology inno
Mar 26, 2026
earnings
Zentalis Pharmaceuticals Reports Full Year 2025 Financial Results and Operational Updates
<p align="justify">SAN DIEGO, March 26, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advan
Mar 24, 2026
earnings_calendar
ZNTL Q4 2025 Earnings After Market Close — 2026-03-24
Mar 17, 2026
routine
Zentalis Pharmaceuticals to Present Two Posters at the American Association for Cancer Research (AACR) Annual Meeting 2026
<p align="justify">SAN DIEGO, March 17, 2026 (GLOBE NEWSWIRE) -- Zentalis<sup>®</sup> Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology inno